Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h.

ABSTRACT:

Background

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized multiple myeloma treatment (MM). However, managing its immune-mediated adverse events, particularly macrophage activation syndrome-like (MAS-like), remains challenging due to underreporting.

Methods

This multicentre, retrospective, analytical study evaluated MM patients treated with the anti-BCMA academic product ARI0002h. MAS-like was defined using the University of California San Francisco (UCSF) consensus criteria. Primary endpoints included baseline characteristics, predictive factors, and survival outcomes associated with MAS-like.

Results

Of 80 patients, 12 (15%) met the UCSF criteria for MAS-like. These pat

SUBMITTER: Munarriz D 

PROVIDER: S-EPMC12571847 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature